Pricing Log in Create free account
Friday 6 November 2026 Export QGEN’s income statement to Excel — free account

QIAGEN N.V.

QGEN Healthcare Diagnostics & Research

QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.

Revenue
+0.28%
EPS
+7.94%
Free cash flow
+30.5%
Total debt
+13.8%

Quarter to June 2026, against a year earlier

50.88 0.05 +0.10%
Market cap
$10.5B
P/E
26.1×
Fwd P/E
26.0×
Dividend yield
0.69%
F-score
8/9
Altman Z
3.94
Beneish M
−2.60
Dividend safety
66/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

QIAGEN N.V. (QGEN) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, QIAGEN N.V. (QGEN) trades at a EV/EBITDA of 17.4×. Over the past ten years it has ranged from 11.4× (September 2022) to 42.6× (December 2019); the current reading is higher than 48% of that period. That is below the Diagnostics & Research industry median of 23.4× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 17.1× (50.21%)
FY2024 34.3× 101.33%
FY2023 17.1× 8.56%
FY2022 15.7× 1.77%
FY2021 15.4× (26.30%)
FY2020 21.0× (39.37%)
FY2019 34.6× 107.15%
FY2018 16.7× (16.51%)
FY2017 20.0× (3.80%)
FY2016 20.8× 18.84%

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 13.7× (10.51%)
Mar 2026 15.3× (10.49%)
Dec 2025 17.1× 14.98%
Sep 2025 14.9× (13.41%)
42 more quarters

Against its own ten years

Low 11.4× High 42.6×
Ten-year median 17.6×
Current reading's percentile 48

EV/EBITDA against peers

Company EV/EBITDA
GRAL GRAIL, Inc. compare n/m
GH Guardant Health, Inc. compare n/m
QGEN QIAGEN N.V. 17.4×
ICLR ICON PLC compare 17.9×
RDNT RadNet, Inc. compare 21.8×
RVTY Revvity Inc. compare 25.1×
MEDP Medpace Holdings, Inc. compare 27.0×
CRL Charles River Laboratories International, Inc. compare 31.2×
BLLN BillionToOne, Inc. compare 86.7×
Diagnostics & Research industry median 23.4×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on QGEN